FDA approves Bevyxxa® (betrixaban) for hospital and extended duration prevention of VTE
Portola announced the FDA has approved Bevyxxa (betrixaban), the first and only anticoagulant for hospital and extended duration prophylaxis (35 to 42 days) of venous thromboembolism in adult patients hospitalized for an acute medical illness who are at risk for thromboembolic complications. June 23, 2017